Syndrome d'hypersensibilité médicamenteuse (mécanismes pharmacologiques et immunologiques et bilan des documents d'informations suite à l'observation de 9 cas)

PARIS-BIUP (751062107) / SudocSudocFranceF

Pristinamycine (actualisation des effets indésirables, suite à de nouveaux cas cliniques de toxidermies)

PARIS-BIUP (751062107) / SudocSudocFranceF

Neuropathies autonomes et périphériques secondaires au bortezomib (caractéristiques clinico-biologiques et évolutives d'une cohorte de patients)

PARIS-BIUP (751062107) / SudocSudocFranceF

Population Pharmacokinetics of Tenofovir in Human Immunodeficiency Virus-Infected Patients Taking Highly Active Antiretroviral Therapy

The influence of renal function on tenofovir pharmacokinetics was investigated in 193 human immunodeficiency virus (HIV)-infected patients by the use of a population approach performed with the nonlinear mixed effects modeling program NONMEM. Tenofovir pharmacokinetics was well described by a two-compartment open model in which the absorption and the distribution rate constants are equal. Typical population estimates of apparent central distribution volume (V(c)/F), peripheral distribution volume (V(p)/F), intercompartmental clearance (Q/F), and plasma clearance (CL/F) were 534 liters, 1,530 liters, 144 liters/h and 90.9 liters/h, respectively. Apparent plasma clearance was related to body weight/serum creatinine ratio (BW/S(CR)) and to the existence of a tubular dysfunction. Concomitant treatment with lopinavir/ritonavir was found to decrease tenofovir clearance. Individual Bayesian estimates of CL/F were used to calculate the tenofovir area under the concentration-time curve from time zero to 24 h (AUC(0-24)). In patients without tubular dysfunction, AUC(0-24) values markedly decreased from 6.7 to 1.4 mg · h/liter for BW/S(CR) increasing from 0.44 to 1.73. The relevance of a dosage adjustment based on BW/S(CR) should be further evaluated